Skip to main content

Table 1 Baseline characteristics of AMI patients by tertiles of systemic-immune inflammation index

From: Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry

Clinical characteristics

Overall

(N = 2111)

Tertiles of systemic-immune inflammation index

 

Tertile 1 (N = 702)

Tertile 2 (N = 706)

Tertile 3 (N = 703)

P-value

 < 613.57

613.57–1136.56

 ≥ 1136.56

 

Age, years

65.2 ± 12.2

65.4 ± 12.0

64.6 ± 12.4

65.5 ± 12.2

0.339

Male sex

1637 (77.5)

534 (76.1)

552 (78.2)

551 (78.4)

0.515

Current smoker

953 (45.1)

303 (43.2)

343 (48.6)

307 (43.7)

0.078

Comorbidities

     

 Hypertension

1342 (63.6)

441 (62.8)

444 (62.9)

457 (65.0)

0.628

 Diabetes mellitus

789 (37.4)

277 (39.5)

258 (36.5)

254 (36.1)

0.377

 Dyslipidemia

565 (26.8)

183 (26.1)

187 (26.5)

195 (27.7)

0.763

 Chronic kidney disease

165 (7.8)

40 (5.7)

61 (8.6)

64 (9.1)

0.036

 History of HF

105 (5.0)

28 (4.0)

33 (4.7)

44 (6.3)

0.133

 History of MI

137 (6.5)

57 (8.1)

41 (5.8)

39 (5.6)

0.098

 History of PCI

187 (8.9)

84 (12.0)

49 (6.9)

54 (7.7)

0.002

 History of stroke/TIA

236 (11.2)

64 (9.1)

87 (12.3)

85 (12.1)

0.104

Admission presentation

     

 STEMI

1272 (60.3)

327 (46.6)

439 (62.2)

506 (72.0)

 < 0.001

 Anterior locationa

654 (51.4)

155 (47.4)

234 (53.3)

265 (52.4)

0.401

 Systolic BP, mmHg

138.5 ± 23.9

139.2 ± 22.7

139.2 ± 23.4

136.9 ± 25.4

0.123

 Heart rate, bpm

79.6 ± 16.7

76.3 ± 15.7

79.6 ± 15.4

83.0 ± 18.2

 < 0.001

 Killip class > I

279 (13.2)

68 (9.7)

76 (10.8)

135 (19.2)

 < 0.001

Laboratory indices

     

 C-reactive protein, mg/L

5.38 (3.17–17.20)

3.97 (3.02–12.80)

5.69 (3.27–17.26)

6.86 (3.17–25.90)

 < 0.001

 Peak TnT, ng/mL

2.97 (0.78–7.98)

1.55 (0.43–4.88)

2.90 (0.97–7.27)

5.36 (1.63–10.00)

 < 0.001

 Serum creatinine, mg/dL

0.95 ± 0.33

0.93 ± 0.31

0.95 ± 0.34

0.98 ± 0.33

0.018

 Leukocyte count, 109/L

9.54 ± 3.04

7.78 ± 2.08

9.30 ± 2.54

11.60 ± 3.13

 < 0.001

 Neutrophil, count 109/L

7.14 ± 2.92

4.88 ± 1.45

6.88 ± 2.00

9.66 ± 2.82

 < 0.001

 Lymphocyte count, 109/L

1.72 ± 0.79

2.22 ± 0.88

1.72 ± 0.62

1.22 ± 0.50

 < 0.001

 Platelet count, 109/L

207.1 ± 59.6

181.5 ± 48.7

206.8 ± 54.8

233.1 ± 63.0

 < 0.001

 Log-transformed SII

2.93 ± 0.31

2.60 ± 0.15

2.91 ± 0.07

3.27 ± 0.18

 < 0.001

Angiographic data

     

 Primary PCI

1778 (84.2)

567 (80.8)

609 (86.3)

602 (85.6)

0.008

 Infarct-related arteryb

    

0.075

 Left anterior descending

626 (51.6)

146 (47.1)

232 (54.7)

248 (51.8)

 

 Right coronary artery

455 (37.5)

127 (41.0)

140 (33.0)

188 (39.2)

 Left circumflex

132 (10.9)

37 (11.9)

52 (12.3)

43 (9.0)

Echocardiographic data

     

 LAD, mm

38.1 ± 4.6

38.3 ± 4.4

38.2 ± 4.7

37.8 ± 4.7

0.171

 LVESD, mm

31.0 ± 5.5

30.7 ± 5.4

30.7 ± 5.3

31.5 ± 5.6

0.015

 LVEDD, mm

45.6 ± 4.8

45.7 ± 4.8

45.5 ± 4.6

45.6 ± 4.9

0.889

 LVEF, %

50.5 ± 10.5

52.7 ± 9.8

51.1 ± 10.2

47.7 ± 11.0

 < 0.001

Medication at discharge

     

 Aspirin

1946 (92.2)

633 (90.2)

662 (93.8)

651 (92.6)

0.037

 ACEI/ARB/ARNI

1262 (59.8)

445 (63.4)

429 (60.8)

388 (55.2)

0.006

 β-blocker

1528 (72.4)

485 (69.1)

511 (72.4)

532 (75.7)

0.022

 Statin

2026 (96.0)

677 (96.4)

679 (96.2)

670 (95.3)

0.528

 Oral anticoagulants

12 (0.6)

6 (0.9)

2 (0.3)

4 (0.6)

0.291

 Diuretics

302 (14.3)

79 (11.3)

102 (14.5)

121 (17.2)

0.006

 Antidiabetic agents

636 (30.1)

220 (31.3)

205 (29.0)

211 (30.0)

0.642

 Insulin

255 (12.1)

68 (9.7)

84 (11.9)

103 (14.7)

0.017

  Metformin

231 (10.9)

88 (12.5)

66 (9.4)

77 (11.0)

0.161

  Sulfonylureas

213 (10.1)

83 (11.8)

71 (10.1)

59 (8.4)

0.104

  Glinides

41 (1.9)

17 (2.4)

11 (1.6)

13 (1.9)

0.490

  Thiazolidinediones

19 (0.9)

9 (1.3)

6 (0.9)

4 (0.6)

0.354

  1. aFor patients with STEMI
  2. bFor patients with STEMI undergoing angiography
  3. AMI acute myocardial infarction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNI angiotensin receptor-neprilysin inhibitor, BP blood pressure, GRACE Global Registry of Acute Coronary Events, HF heart failure, LAD left atrial diameter, LVEDD left ventricular end-diastolic diameter, LVEF left ventricular ejection fraction, LVESD left ventricular end-systolic diameter, PCI percutaneous coronary intervention, SII systemic-immune inflammation index, STEMI ST-segment elevation myocardial infarction, TIA transient ischemic attack